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 I Purpose
A three-step legal framework of early warning, risk 
assessment and control measures allows the European 
Union to rapidly detect, assess and respond to the public 
health and social threats caused by new psychoactive 
substances in Europe. The European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) is responsible for 
the first two steps of this system, namely operating the EU 
Early Warning System on new psychoactive substances in 
close cooperation with Europol and conducting risk 
assessments. The European Commission is responsible for 
proposing control measures.
The purpose of this report is to provide a high-level 
overview of the situation in Europe regarding new 
psychoactive substances to support stakeholders with 
their ongoing preparedness planning and response 
activities in relation to the public health and social threats 
caused by these substances, within the context of the 
coronavirus disease (COVID-19) pandemic. The report is 
based on the EMCDDA’s early warning and risk 
assessment activities from 1 January 2019 until 
31 October 2020 and includes an assessment of 
information reported through the EU Early Warning System 
and supplemented with other information available to the 
Agency. This includes case reports of event-based data, 
including data on law enforcement seizures and serious 
adverse events (typically reports of acute poisonings and 
deaths), aggregated law enforcement seizure data and 
information from partners in Europe, third countries and 
international organisations, as well as the grey and 
scientific literature. It also includes the key findings of the 
initial report on and risk assessment of isotonitazene 
— a potent opioid of the benzimidazole family, of which 
five members have now appeared on the drug market in 
Europe and which may replace fentanyl derivatives — and 
the initial reports on MDMB-4en-PINACA and 4F-MDMB-
BICA, both potent synthetic cannabinoids, which together 
are linked to at least 25 deaths in Europe in 2020. In 
addition, the report takes into consideration some of the 
possible impacts of the COVID-19 pandemic on the 
availability, supply, and use of, and harms resulting from 
new psychoactive substances.
Statement on the United Kingdom
The United Kingdom had left the European Union as 
of 1 February 2020. However, during the transitional 
period, the United Kingdom continues to participate 
in the European Union Early Warning System on new 
psychoactive substances. Unless stated otherwise, 
for the purpose of this report, the term ‘Member 
States’ includes the United Kingdom.
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 I Introduction
 I Background
New psychoactive substances make up a broad range of 
drugs that are not controlled by the United Nations 
international drug laws. They include synthetic 
cannabinoids, stimulants, benzodiazepines (and other 
sedative-hypnotics), opioids, hallucinogens and 
dissociatives. Many of these substances are intended to 
mimic the effects of internationally controlled drugs and 
are traded as ‘legal’ replacements for them. While new 
substances have always appeared on the drug market, 
since around 2008 there has been a large increase in the 
number, type and availability of and, subsequently, harms 
caused by these substances in Europe and, increasingly, 
elsewhere, including the United States, Russia, Australia 
and New Zealand.
Much of the growth in this market has been due to a shift 
from the production of a handful of substances in relatively 
small-scale illicit laboratories to production in chemical 
and pharmaceutical companies operating predominantly 
in China which are capable of mass-producing a large 
range of new psychoactive substances. This has been 
driven by globalisation and new technologies, such as the 
internet, allowing new psychoactive substances to be 
produced, sold and supplied on an industrial scale. These 
factors create a resilient and highly dynamic new 
psychoactive substances market, making it more difficult 
to disrupt.
Despite this resilience, there have been some encouraging 
developments in Europe, which have been particularly 
visible from around 2015 onwards. These include 
a decrease in the number of new substances identified for 
the first time each year and an overall decrease in seizures 
of new substances, largely driven by a drop in seizures of 
synthetic cannabinoids and cathinones — the two largest 
groups of new substances monitored by the EMCDDA. In 
part, these changes appear to be related to a disruption in 
the ‘legal high’ trade, which for a period saw new 
psychoactive substances being sold openly on the high 
street in many countries in Europe. More generally, broader 
policy responses designed to restrict the availability of new 
psychoactive substances are also likely to have had an 
effect. However, since 2015 a greater proportion of 
substances associated with problematic use — 
particularly opioids (see Section ‘Opioids’) and 
benzodiazepines (see Section ‘Benzodiazepines’) — have 
appeared on the market, bringing a new set of problems, 
while the market in synthetic cannabinoids, once the 
epitome of the ‘legal highs’ phenomenon, has also evolved 
to pose a threat to health security (see Section ‘Synthetic 
cannabinoids’) (EMCDDA, 2018). During this time, the new 
psychoactive substances market has also developed 
stronger links with markets in established controlled drugs.
 I  Global markets, glocal threats and the COVID-19 pandemic
Over the past decade, the globalisation of drug markets 
and new technologies have led to an increase in the 
number and types of risks for people who use both new 
psychoactive substances and controlled drugs. These risks 
relate both to the increase in the availability of a large 
range of new substances on the drug market, including 
new products and new ways of buying and using them, and 
to the emergence of new user groups.
The appearance of a substance in a new geographical area 
or new groups of users should always be a cause of 
concern for public health, as, at least initially, the 
population will have little or no experience of its effects 
and how to use it. Similar concerns apply to new ways of 
using a substance, new products and new patterns of use. 
While some risks might be known, others are unknown and 
some will not become known until larger numbers of 
people have been exposed to the substance. In addition, 
the very nature of unregulated markets means that these 
risks may be amplified by uncertainty regarding the doses 
that are used, and the potential for the substance to be 
substituted for or adulterated with another substance, all 
without the knowledge of the user.
A growing number of highly potent substances that pose 
a high risk of acute poisoning are also being reported. 
These include synthetic cannabinoids, opioids, 
benzodiazepines and a range of other substances. Strong 
links also exist between the trade in new psychoactive 
substances and markets in established controlled drugs, 
with the increasing use of new benzodiazepines to make 
fake versions of common anti-anxiety medications, such 
as fake alprazolam (Xanax) and diazepam, indicating this. 
The use of new psychoactive substances by high-risk drug 
users and other marginalised and vulnerable populations 
also appears to have increased in some places, including 
in prisons. In addition, unregulated, globalised supply 
chains and markets, where new psychoactive substances 
and related ingredients can be manufactured in one 
country, brokered and used to make products in another 
country and, finally, used in other countries still, increase 
the opportunity for miscommunication, substitution, 
mislabelling, adulteration, contamination and dilution of 
new psychoactive substances and controlled drugs with 
a range of potentially dangerous and sometimes highly 
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toxic substances. The recent detection of the rat poison 
brodifacoum in synthetic cannabinoid smoking mixtures in 
the United States is an example of this (Moritz et al., 2018; 
US CDC, 2018). Overall, these types of substances pose 
a high risk of life-threatening poisoning to users and are 
capable of causing outbreaks of mass poisonings 
(Adamowicz, 2016; Adams et al., 2017; Andonian et al., 
2017; Arens et al., 2016; Edison et al., 2017; Horth et al., 
2018; Kasper et al., 2015, 2019; Klar et al., 2016; Los 
Angeles County Department of Public Health, 2016; Monte 
et al., 2014; Moritz et al., 2018; Pap, 2016, 2018; 
Papadopoulos et al., 2017; Schwartz et al., 2015; Shevyrin 
et al., 2015; Springer et al., 2016; Sutter et al., 2017; 
Tomassoni et al., 2017; Trecki et al., 2015; Tyndall et al., 
2015; US CDC, 2013, 2018; Vallersnes et al., 2009). Such 
mass casualty incidents are generally characterised by 
sudden and unexpected cases of acute poisoning that can 
range from several to hundreds of victims, and can rapidly 
overwhelm first responders, first receivers and, more 
generally, local healthcare systems. While formal 
estimates are lacking, responding to such outbreaks is also 
invariably financially costly. Such substances can also 
pose serious cross-border threats to health (European 
Parliament and Council of the European Union, 2013, 
2017a,b; WHO, 2015), especially as a result of the growth 
of online markets (EMCDDA, 2017).
Despite the globalised nature of the market, the threats 
posed in a particular area are shaped by the interaction of 
a range of global and local — ‘glocal’ — factors. These 
include the availability and supply of new psychoactive 
substances, as well as the local drug situation (including 
drug supply and use, public health and social problems, 
drug policy and responses) and the physical, social, 
cultural, economic and political environment, country size, 
population, structure, geography, healthcare, public health 
systems and resources.
COVID-19 pandemic
The COVID-19 pandemic has brought into sharp focus the 
importance of ‘complex, transboundary, multifactorial’ 
approaches to tackling health challenges, the need to 
strengthen health security and the interconnected nature 
of health in our globalised world (Mackenzie and Jeggo, 
2019; Wolicki et al., 2016). Adding to the complexity of the 
new psychoactive substances market, the pandemic and 
related response measures — such as the closure of 
public spaces and ‘stay-at-home’ measures — bring new 
challenges arising from the resulting effects on existing 
drug markets, drug use, drug services and other response 
measures in many, and perhaps unpredictable, ways at 
different times. As part of preparedness planning, scenario 
planning allows planners and practitioners to plan for 
uncertainty and prepare for the worst — to think the 
unthinkable. Such a proactive approach may be better 
informed if we consider how the COVID-19 pandemic may 
adversely interact with the existing drugs and NPS 
problem (and vice versa) exacerbating the health and 
social harms caused by both. Such a syndemic-like state, 
or synergistic epidemic, has the potential to increase 
vulnerability and negative outcomes for people who use 
drugs and society in general.
The effect of the pandemic on the drug situation, including 
the new psychoactive substances market, is likely to 
become increasingly important as countries in Europe face 
the second wave of the outbreak during autumn and winter 
2020 and into 2021. Reflecting the complexity of the 
current situation, the title, and theme, of this report is New 
Psychoactive Substances: Global Markets, Glocal Threats 
and the COVID-19 Pandemic. It aims to encourage the 
reader to think about how the issues highlighted, and more 
generally how the availability and use of new psychoactive 
substances, may apply to their country, region or 
neighbourhood, as well as how the pandemic may have an 
impact. This requires consideration of what the current and 
future threats and vulnerabilities may be, as well as what 
practical, actionable measures are needed to deal with 
them — whether this be prevention, health protection, 
treatment and supply reduction measures, or policy 
development and implementation. It will also require 
consideration of what resources are available to respond 
to health threats, including relevant capacity and 
capability. For example, it is important to consider that the 
same personnel (public health personnel, health 
professionals and law enforcement personnel) and 
resources used to respond to outbreaks caused by new 
psychoactive substances will be the same as those used 
to respond to COVID-19 outbreaks.
In April 2020, the EMCDDA issued an alert to the EU Early 
Warning System Network across Europe, highlighting the 
potential impact of the pandemic on drug markets and risks 
to people who use drugs, and the need for a high level of 
vigilance to ensure early detection, reporting, assessment 
and responses to changes to the drug markets that may 
have a high impact on public health (EMCDDA, 2020a).
Although evidence is currently limited, based on previous 
experiences of disruptions to drug markets, the impact of 
the pandemic could lead to localised or broader changes in 
drug use and patterns of use, as well as an increased risk 
of substitution, misselling, adulteration, contamination and 
dilution with a range of potentially dangerous and 
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sometimes highly toxic substances; in some cases, this 
could cause outbreaks of mass poisonings, which could 
overload healthcare systems already struggling with 
the pandemic.
These may be single ‘one off’ events or short-lived or longer 
lasting changes. Laboratory (analytically) confirmed 
reports from forensic and toxicology laboratories will 
continue to play a central role in the early detection of and 
response to such events and changes. It is also important 
to note that, in some settings, there may be a risk of delays 
in detecting, reporting, assessing and responding to 
changes in drug markets, and resulting harms due to the 
potentially reduced capacity of early warning systems, 
including forensic and toxicology laboratories, as a result 
of the pandemic. It is important for public health protection 
that, where possible, and according to relevant policies 
and procedures, changes to drug markets and related 
events that may have a high impact on public health 
continue to be reported in a timely manner to the 
relevant agencies.
Early detection, reporting, assessment and response
There is much speculation about, but currently only limited 
data to analyse and assess, the impact of the pandemic on 
the availability, supply and use of new psychoactive 
substances. Providing reliable information is critical to 
facilitate an effective public health response, including 
prevention, health protection, treatment, supply reduction, 
and policy development and implementation. The EU Early 
Warning System and national early warning systems play 
a central role by providing such information in a timely 
manner and in sufficient detail to the right people, in the 
right place, at the right time, to allow them to assess the 
information and, where necessary, respond through timely 
and effective actions to prevent or reduce the risk of harm 
(EMCDDA, 2020b).
The different types of response actions taken depend on 
the substance of interest, the type and level of threat, the 
individuals who are at risk and the roles of the 
organisations and people who are responding. Actions may 
be taken at the levels of practice, research and policy.
For example, at national level, the formal notification of 
a new psychoactive substance (see Section ‘Overview of 
notifications’) ensures that the Early Warning System 
Network across Europe is alerted as soon as possible 
when a new psychoactive substance is identified for the 
first time on the European drug market (EMCDDA, 2018). 
This allows the network to detect and assess any potential 
threats, as well as to identify and implement any response 
measures that might be required. Importantly, the 
information provided in the formal notification allows 
forensic and toxicology laboratories to include the 
substance in their analytical screening, allowing it to be 
identified and therefore monitored for in law enforcement 
seizures and serious adverse events (such as acute 
poisonings and deaths).
Actions may also include communicating risk to relevant 
agencies, as well as to people who use drugs, such as 
when a toxic or otherwise dangerous substance or 
situation is detected, and ensuring that sufficient 
preparations have been made to deal with a situation that 
has the potential to cause an outbreak, including mass 
poisoning events. Related to this, actions may also extend 
to ensuring that there is a sufficient supply and sufficient 
availability of medical countermeasures, such as the opioid 
antidote naloxone, should there be a sudden increase in 
the availability of highly potent opioids.
As the amount of information is usually limited when 
a substance is first identified on the drug market, actions 
may also include research to better understand the risks of 
a particular substance. This may include research to 
understand its pharmacological and toxicological effects 
and its epidemiology (who is using the substance, how 
many people are using it and how it is being used, etc.).
In other cases, actions may include formal risk assessment 
at national level or by the EMCDDA at European level, 
which may lead to control or other types of restrictive 
measures that are intended to reduce the supply and 
availability of a substance.
Within this context, the report discusses recent 
developments in the market and use of new psychoactive 
substances, and highlights some of the major emerging 
issues and threats. These include developments in the 
markets for synthetic cannabinoids, opioids and 
benzodiazepines. Finally, the report highlights the need to 
continue to invest in developing and maintaining strong 
early warning and response systems for new psychoactive 
substances and illicit drugs to protect public health.
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 I Situation in Europe
 I Overview of notifications
By 31 October 2020, the EMCDDA was monitoring more 
than 820 new psychoactive substances that have 
appeared on Europe’s drug market since monitoring began 
in 1997 (Figure 1). This includes 53 substances that were 
notified for the first time in 2019 (Annex 1) and 38 
substances that had been notified in 2020 (up to the end 
of October) (Annex 2). This represents a decrease from the 
close to 100 new psychoactive substances introduced to 
the European market each year between 2014 and 2015. 
At least in part, this drop in notifications is likely to reflect 
the results of sustained efforts to control and otherwise 
restrict the sale of new substances in Europe, particularly 
their open sale as ‘legal highs’, which in many countries 
included open sale on the high street (Evans-Brown and 
Sedefov, 2018). It may also reflect control measures in 
source countries, such as China, aimed at restricting the 
production and trade of these substances.
Despite the general decrease in the number of substances 
newly introduced to the European market each year, since 
2015 approximately 400 previously reported new 
psychoactive substances have been identified each year 
(Figure 2). This suggests that many substances remain in 
circulation, albeit in varying amounts. Among other 
problems, this can increase the risk of them being sold 
either deliberately or accidentally as other drugs. In some 
cases, such as when synthetic cannabinoids are sold as 
ecstasy, this has caused outbreaks of mass poisonings.
Key methodological points
Data regarding first identifications in Europe (formal 
notification data) relate to the period from 1 January 
2005 to 31 October 2020.
The seizure data used in this report are from 
1 January 2005 to 31 December 2019.
Law enforcement seizures of new psychoactive 
substances reported to the EMCDDA should be 
understood as minimum values. This is because data 
are drawn from case reports rather than routine 
monitoring systems. Reports are influenced by 
a range of factors such as increasing awareness of 
new substances, their changing legal status, law 
enforcement capacities and priorities, the reporting 
practices of agencies and the structure of national 
early warning systems (which differ widely across 
Europe). The seizure data are not directly comparable 
with the data on established controlled drugs. 
Quantitative data on the amount of new psychoactive 
substances present in a seizure (purity) are typically 
not available, as this type of analysis is not routinely 
performed by laboratories. As a result, seizures are 
not adjusted for purity. Seizures are also not adjusted 
for the potency of the substance. In addition, a new 
psychoactive substance may be found in a mixture 
with one or more new psychoactive substances and, 
in such cases, the first new psychoactive substance 
reported by the laboratory is taken as the substance 
in the seizure.
The data also include an increasing number of 
formerly identified new psychoactive substances 
that are now controlled under the United Nations 
international drug laws. These include 2C-B, GHB, 
some synthetic cathinones (such as mephedrone), 
synthetic cannabinoids (such as 4F-MDMB-BINACA) 
and opioids (such as carfentanil).
The figures depicting trends in the quantity of 
material seized aggregate quantities for all forms 
reported in mass (kg) and exclude all material 
reported as tablets (units), volume (litres) and/or 
other forms. Trends are presented for the EU Member 
States (EU) and the EU Member States plus Norway 
and Turkey (EU+2).
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FIGURE 1
Numbers and categories of new psychoactive substances reported to the EU Early Warning System for the first time, 
2005-2020 (up to 31 October)
FIGURE 2
Numbers and categories of new psychoactive substances detected each year, following their first identification, 2005-2019
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 I Overview of seizures, 2019
The number and amount of new psychoactive substances 
seized by law enforcement agencies in Europe rose sharply 
until 2015. Since then, this trend seems to have stabilised 
or reversed towards a decline, depending on the region. 
During 2019, 42 385 seizures of new psychoactive 
substances were reported to the EU Early Warning System; 
of these, 29 621 seizures were reported by EU Member 
States (Figure 3). Together, this represents a decrease of 
42 % and 51 %, respectively, in the number of seizures 
compared with those reported in 2015.
In 2019, seizures of more than 2.8 tonnes of new 
psychoactive substances, mostly in the form of powders, 
were reported to the EU Early Warning System; of this 
total, approximately 2.2 tonnes were reported by the EU 
Member States. Together, this represents a decrease of 
47 % and 56 %, respectively, in seizure quantities 
compared with those reported in 2015. In addition, 976 
litres of liquids and 3.3 million tablets and capsules were 
also found to contain new psychoactive substances. 
Seizures of new psychoactive substances continue to be 
dominated by synthetic cannabinoids and cathinones, 
which together accounted for 62 % of all seizures reported 
in 2018 (47 % for the EU Member States) (Figure 4).
FIGURE 3
Seizures of new psychoactive substances reported to  
the EU Early Warning System: trends in total numbers  
of seizures, 2005-2019, and percentages of seizures  
by category in 2019 (EU and EU+2)
Note: The ‘plants and extracts’ category is excluded from the 
seizure data presented.
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FIGURE 4
Seizures of new psychoactive substances reported to the 
EU Early Warning System: trends in quantity of material 
seized, for all forms reported in mass (2005-2019)  
(EU and EU+2)
Note: The ‘plants and extracts’ category is excluded from the 
seizure data presented.
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Despite the decrease in seizures of new psychoactive 
substances in Europe, their overall availability and 
accessibility appears to be relatively high. It remains easy 
to buy substances on demand from online suppliers in both 
wholesale and retail amounts (Evans-Brown and Sedefov, 
2018), while in some regions some new substances are 
also commonly sold at street level, often as part of the 
existing drug market. In the latter case, this includes new 
benzodiazepines, such as etizolam, which are increasingly 
used to make fake benzodiazepine medicines.
 I Opioids
While currently playing a small role in the overall market, 
new opioids are of particular concern for public health 
because they pose a high risk of life-threatening poisoning, 
as an overdose can cause respiratory depression. Since 
2009, a total of 66 new opioids, many of which are highly 
potent, have been identified on the drug market in Europe 
— including nine that have been reported during 2020 so 
far. Similar to 2019, only one of these opioids reported in 
2020 was a fentanyl derivative, isobutyrfentanyl, which is 
a much smaller proportion than in previous years (Figure 5). 
The remaining eight opioids (etazene, brorphine, 
metodesnitazene, nortilidine, metonitazene, carbonyl-
bromadol, AP-238 and O-AMKD) are all chemically 
different from fentanyl, despite giving rise to similar 
concerns in respect to toxicity.
In 2019, approximately 439 seizures of new opioids were 
reported to the EU Early Warning System (435 (99 %) of 
which were reported by the Member States), representing 
around 2 % of the total number of seizures of new 
psychoactive substances. This amounted to approximately 
17 kg of material (almost 95 % were fentanyl derivatives), 
of which 12 kg was in the form of powders (almost 91 % 
were fentanyl derivatives, of which almost 84 % was 
carfentanil) (Figure 6) (Table 1). This is an increase from 
the total quantity of 1.9 kg reported in 2018, which was 
almost exclusively due to a single large seizure of 
approximately 10 kg of carfentanil reported by Latvia. 
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Numbers and types of new synthetic opioids notified to the 
EU Early Warning System for the first time, 2005-2020
FIGURE 6
Seizures of opioids reported to the EU Early Warning 
System: trends in numbers of seizures and quantities 
seized, reported in mass, 2005-2019 (EU and EU+2)
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Moreover, seizures amounting to 41 millilitres of liquids and 
853 tablets and capsules (excluding tramadol) were also 
reported. The high potency of some new opioids means 
that even small quantities could yield many thousands of 
street doses.
Less commonly, new opioids have also been found in 
blotters, herbal smoking mixtures and fake benzodiazepine 
medicine tablets (such as fake Xanax tablets). In these 
cases, there may be no indication to users that they 
contain potent opioids, posing a poisoning risk, particularly 
for people with no existing tolerance to opioids.
Initially, much of the growth of the market in new opioids in 
Europe was driven by an increase in the availability of 
derivatives of fentanyl, such as carfentanil and 
cyclopropylfentanyl, between 2016 and 2018. Fentanyl is 
a highly potent opioid widely used in human medicine in 
anaesthesia and for pain management. Fentanyl 
derivatives are highly potent and difficult to dose, and thus 
pose a very high risk of fatal poisoning. Reflecting this, 
more than 250 deaths involving fentanyl derivatives were 
reported to the EU Early Warning System during 2016 and 
2018, while thousands of deaths have been reported in the 
United States and Canada.
However, since 2019, the market in Europe has changed. 
Fewer new fentanyl derivatives have been identified for the 
first time, while more ‘obscure’ groups of opioids have 
been identified. These include piperidylthiambutene, 
AP-237, 2-methyl-AP-237, AP-238, 2F-viminol, brorphine 
and substances from the highly potent benzimidazole 
group of opioids — isotonitazene, etazene, 
metodesnitazene and metonitazene. While the causes of 
this shift away from fentanyl derivatives are unclear, the 
shift coincides with the introduction of generic control 
measures for fentanyl derivatives in China, where many of 
these substances are manufactured (UNODC, 2019). 
A similar policy response in the United States as well as 
responses in Europe to restrict availability may also have 
played a role (US DEA, 2018).
During 2020, signals related to isotonitazene led the 
EMCDDA to launch an initial report (EMCDDA, 2020c) on 
the substance because of concerns of potential EU-level 
threats, resulting in a risk assessment of this substance 
being carried out in May 2020.
Focus on isotonitazene
During the mid-1950s, attempts to develop better and 
safer opioid analgesics led to the discovery of a series of 
2-benzylbenzimidazole compounds with levels of 
analgesic potency several orders of magnitude higher than 
that of morphine. This group of structurally distinct opioid 
analgesics includes isotonitazene, which first appeared on 
the European drug market in March 2019, as well as 
etonitazene and metonitazene, which are closely related 
homologues, and clonitazene. Both etonitazene and 
clonitazene are controlled under the United Nations Single 
Convention on Narcotic Drugs of 1961 (ECAPD, 1961; 
UNODC, 2019).
Although isotonitazene was first synthesised in the 
mid-1950s (Hoffmann et al., 1959, 1960; Hunger et al., 
1960a), no additional reports related to the substance 
could be found prior to its identification on the illicit drug 
market in 2019 (Blanckaert et al., 2020; EMCDDA, 2020c; 
Ujváry, 2020).
Isotonitazene has been available on the drug market in 
Europe since at least April 2019 and has been identified in 
six countries (Belgium, Estonia, Germany, Latvia, Sweden 
and the United Kingdom). Law enforcement seizures have 
been reported by four Member States (Estonia, Germany, 
(a) Opioids Number of seizures
Carfentanil 234
Furanylfentanyl 43
Isotonitazene 25
2-methyl-AP-237 23
Ocfentanil 16
(b) Opioids Powder (grams)
Carfentanil 10 044.2
Tianeptine 783.5
Methoxyacetylfentanyl 485.1
Isotonitazene 110.0
Piperidylthiambutene 100.2
(c) Opioids Tablets (units)
2F-viminol 497
2-methyl-AP-237 213
U-47700 126
TABLE 1
The most commonly seized opioids reported to the EU Early Warning System: numbers of seizures (a) and quantities 
seized reported in mass (b) and units (c), 2019
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Latvia and Sweden). The most recent identification of 
isotonitazene reported to the EMCDDA was from a seizure 
made in May 2020.
As isotonitazene has only recently emerged on the drug 
market in Europe (Figure 7), it is important to note that its 
presence on the drug market and it being the cause of 
serious adverse events may be undetected, since the 
substance is not routinely screened for in some 
laboratories. In addition, the ongoing COVID-19 pandemic 
may have reduced the capacity of early warning systems 
to detect and report events involving isotonitazene.
It appears that at least some of the isotonitazene on the 
market in Europe has been supplied from China. 
Isotonitazene is sold online as a powder in wholesale and 
small amounts; it is also sold as ready-to-use nasal sprays. 
Isotonitazene is also sold on the illicit drug market, 
including, it appears, on street-level opioid markets. Based 
on the limited information, it is presumed, but not 
confirmed, that isotonitazene is being injected 
intravenously by high-risk opioid users in some parts of 
Europe.
Isotonitazene can be administered in a range of ways. 
These include orally, intranasally, by smoking or vaporising, 
and by injection.
A total of two deaths involving isotonitazene have been 
reported to the EMCDDA by Germany and the United 
Kingdom, although few additional details are currently 
available on these cases. Deaths have also been reported 
in Canada (three cases) and the United States (18 cases). 
In the latter case, at least some of the individuals were 
high-risk drug users and included people who had a history 
of injecting illicit opioids such as heroin. Polydrug use, 
especially the use of two or more central nervous system 
depressants (which increases the risk of life-threatening 
respiratory depression), was also common in these 
individuals.
As isotonitazene has only recently emerged on the drug 
market, there is limited information on the substance. In 
particular, formal epidemiological studies have not been 
conducted, which limits understanding of the frequency 
and patterns of use.
Although the size of the market is unknown, isotonitazene 
is sold online as a legal replacement for controlled opioids; 
it also appears to have been sold on the illicit opioid market 
at street level in a few countries. Similar to other opioid 
analgesics, the most serious acute health risk from using 
isotonitazene is likely to be respiratory depression, which 
in the event of an overdose could lead to apnoea, 
respiratory arrest and death.
Since the risk assessment on isotonitazene was carried 
out, a further three benzimidazole opioids have been 
identified on the European drug market — etazene 
(Figure 8), metodesnitazene and metonitazene — 
suggesting that this group of substances may replace 
fentanyl derivatives. In an animal model of analgesia, 
etazene was assessed to be 70 times as potent as 
morphine (Hunger et al., 1960a,b).
1 Early warning Initial report 2 Risk assessment 3 Control measures
Regulation (EC) 1920/2006 (as amended by Regulation (EU) 2017/2101)
Council Framework
Decision 2004/757/JHA (as amended 
by Directive (EU) 2017/2103)
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FIGURE 7
Timeline of EU early warning and response actions to the potent opioid isotonitazene
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 I Synthetic cannabinoids
When synthetic cannabinoids first appeared on the market 
in Europe around 2006, they were sold as legal 
replacements for cannabis. While this continues to be the 
case, they have also gained a reputation for having powerful 
intoxicating effects and, as a result, some users use them 
specifically for this reason. Although synthetic cannabinoids 
are used recreationally, in some places they are also used by 
people experiencing homelessness, prisoners and other 
vulnerable groups because of the profound intoxication they 
can cause while being cheaper than other drugs. They also 
continue to be used by those who are subjected to drug 
testing procedures, including those in prison or undergoing 
drug treatment, as some tests cannot detect synthetic 
cannabinoids that have recently appeared on the drug 
market. Although limited, there is some information to 
suggest a recent increase in the vaping of synthetic 
cannabinoids using electronic cigarettes by young people, 
including teenagers, in some parts of Europe; in some 
FIGURE 8
Nasal sprays and powder containing the potent opioid etazene seized by Finnish customs in March 2020 and June 2020, 
respectively
FIGURE 9
Typical A4-sized papers impregnated with synthetic cannabinoids 
Photos © Finnish Customs, 2020.
Note: The papers, seized in a prison in Scotland, United Kingdom, during 2019, were impregnated with MDMB-4en-PINACA and 5F-MDMB-PICA. 
Photos © Dr Craig McKenzie, Leverhulme Research Centre for Forensic Science, University of Dundee
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cases, the users believed that they were using cannabidiol 
(CBD) or tetrahydrocannabinol (THC).
Three main types of products containing synthetic 
cannabinoids are sold on the drug market. Typically, these 
cannabinoids are sprayed on to or mixed with herbal plant 
material or tobacco and smoked as a joint or inhaled from 
a vaporiser or bong. In recent years, there has also been an 
increase in e-liquid products, where a solution of the 
cannabinoid is prepared by mixing it with a solvent, which 
is then vaped using an electronic cigarette. In addition, it 
appears that an increasingly commonly approach to 
smuggling synthetic cannabinoids into prison in some 
countries is by impregnating paper with the cannabinoids 
— including letters, greeting cards, photographs and 
children’s drawings; images of crossword puzzles, Sudoku 
puzzles and print outs from online catalogues are also 
common (Figure 9). The cannabinoids are then smoked 
with tobacco or vaped using an electronic cigarette. To 
a lesser extent, users may prepare their own similar 
products using cannabinoids in powder form purchased 
from a vendor or dealer. Paper impregnated with 
cannabinoids can pose a high risk of poisoning because 
the amount of cannabinoid can vary greatly in different 
parts of the paper (Norman et al., 2020).
Because of their high potency and the unintentionally high 
doses that users may be exposed to, synthetic 
cannabinoids can pose a high risk of severe poisoning, 
which in some cases can be fatal. These factors could also 
have been responsible for the outbreaks of mass 
poisonings seen with synthetic cannabinoids, which have 
ranged from a handful of people to over 800, some of 
whom have died (Figure 10). While many of the outbreaks 
reported so far have been in the United States, they have 
also occurred in Russia, Canada and Europe. Increasingly, 
some of these outbreaks are due to misselling or 
adulteration. For example, in Europe, outbreaks have been 
caused by synthetic cannabinoids sold as ecstasy, while, in 
Canada and the United States, outbreaks have been 
caused by adulterating opioids such as heroin with 
synthetic cannabinoids (Cruz et al., 2019; EMCDDA, 2018; 
NPS Discovery, 2018). Such outbreaks have the potential 
to overwhelm local healthcare systems, which is of 
particular concern given the ongoing COVID-19 pandemic 
and the additional burden already on healthcare systems 
as a result. With the increased popularity of CBD products, 
synthetic cannabinoids have also been identified in 
e-liquids sold as CBD in Europe. Another concerning 
development is the increase in the identification of 
synthetic cannabinoids in low-THC cannabis products in 
Zurich, Switzerland (Saferparty, 2020). Overall, such 
FIGURE 10
Timeline of major events involving synthetic cannabinoids since they first appeared on the drug market in 2006
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adulterated products pose a high risk of poisoning to 
users. Although the information is limited, similar 
adulteration has also been reported in at least three 
Member States since July 2020.
By the end of October 2020, the EMCDDA was monitoring 
207 synthetic cannabinoids that have appeared on the 
drug market since 2008. These include nine reported for 
the first time in 2020 (up to the end of October). Whereas 
an average of 27 cannabinoids appeared each year in 
Europe between 2011 and 2015, since 2016 the number 
has dropped to around 10 (Figure 11).
In 2019, 19 705 seizures of synthetic cannabinoids were 
reported to the EU Early Warning System, which 
represents around 46 % of the total number of seizures 
reported during that year (25 % in the Member States). In 
the European Union, most of these detections were in the 
form of herbal plant material (5 977 cases, 138 kg) and in 
powders (728 cases, 84 kg) (Figure 12) (Table 2). In recent 
years, there has been a marked decrease in both the 
number of new cannabinoids appearing on the market and 
the quantity of powders and herbal material containing 
synthetic cannabinoids seized in the European Union. 
Overall, these developments may in part reflect a decrease 
in large-scale processing of synthetic cannabinoids into 
herbal smoking mixtures, particularly the ‘legal high’ 
products that typified a large part of the new psychoactive 
substances market between 2008 and 2015. Nonetheless, 
relatively large amounts of bulk powders sufficient to make 
many hundreds of thousands of street doses continue to 
be seized at Europe’s borders each year.
During 2020, signals related to two synthetic 
cannabinoids, MDMB-4en-PINACA (EMCDDA, 2020d) and 
4F-MDMB-BICA (EMCDDA, 2020e), led the EMCDDA to 
launch initial reports on the substances because of 
concerns of potential EU-level threats.
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FIGURE 11
Number of synthetic cannabinoids formally notified to the 
EU Early Warning System for the first time, 2005-2020 
(EU and EU+2)
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FIGURE 12
Seizures of synthetic cannabinoids reported to the EU 
Early Warning System: trends in number of seizures and 
quantity of powders and herbal smoking mixtures, 
reported in mass, 2005-2019 (EU and EU+2)
Note: Seizures reported by Turkey do not specify the physical form. 
As such, the differences between EU and EU+2 dataset cannot be 
distinguished when the data is broken down by physical form.
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Focus on MDMB-4en-PINACA
MDMB-4en-PINACA has been available on the drug market 
in Europe since at least 2017. The substance is sold as 
a ‘legal’ replacement for cannabis and other controlled 
synthetic cannabinoids. Limited information suggests that 
MDMB-4en-PINACA is a potent CB
1
 receptor agonist and, 
as such, shares some pharmacological similarities with 
THC, which is responsible for the major psychoactive 
effects of cannabis and other synthetic cannabinoids, such 
as JWH-018, which are under international control.
As at October 2020, MDMB-4en-PINACA had been 
identified in 20 Member States, as well as in Norway and 
Turkey, and 768 seizures had been reported, including 
seizures of approximately 47 kg of powder and 4.7 kg of 
smoking mixtures. Although MDMB-4en-PINACA was first 
identified on the drug market in 2017, it has been only 
since 2019 that there has been a large increase in the 
number of Member States identifying the substance for 
the first time. In addition, during 2020 there was a large 
increase in the quantity of MDMB-4en-PINACA seized by 
customs, with approximately 99 % of the total amount of 
powder (44 kg) being seized by customs between April 
and June 2020.
A total of 11 acute non-fatal poisonings associated with 
confirmed exposure to MDMB-4en-PINACA have been 
reported by the United Kingdom. The cases occurred 
between January and August 2020. While exposure to 
other substances was also reported in most cases, 
including other synthetic cannabinoids, at least some of 
the clinical features of the poisonings were consistent with 
exposure to synthetic cannabinoids. In 10 of the cases, the 
poisoning was reported to be life threatening and required 
the individual to be hospitalised.
A total of four deaths associated with confirmed exposure 
to MDMB-4en-PINACA have been reported by Sweden and 
the United Kingdom. The deaths occurred between 
January 2019 and June 2020. In three of the cases, 
MDMB-4en-PINACA was reported to have been the cause 
of death or to have contributed to the death.
In prisons, alongside the adverse health effects, the market 
in synthetic cannabinoids has been linked to an increase in 
aggression, violence, bullying and debt. In some cases, this 
has caused a serious threat to the overall safety and 
security of the prison environment. This is a concern given 
that six Member States have reported seizures of 
MDMB-4en-PINACA in prisons and other custodial 
settings and that, overall, approximately 15 % of all 
seizures of MDMB-4en-PINACA made by police occurred 
in these settings.
MDMB-4en-PINACA is subject to restrictive measures in 
14 Member States, Norway and Turkey. It is unknown if 
MDMB-4en-PINACA is controlled in China, from where at 
least some of the substance on the European market has 
been sourced.
Based on the information reported to the EMCDDA, there 
are indications that MDMB-4en-PINACA has the potential to 
continue to spread rapidly in Europe. Of note is that, similar 
to 4F-MDMB-BICA, which is also the subject of an initial 
report (EMCDDA, 2020e), the recent increase in seizures of 
consignments of bulk powder MDMB-4en-PINACA made by 
European customs agencies appears to have coincided with 
the decision to internationally control two closely related 
synthetic cannabinoids commonly found on the drug market 
in Europe: 4F-MDMB-BINACA and 5F-MDMB-PICA. 
Therefore, it is possible that MDMB-4en-PINACA will be 
a replacement for these substances.
(a) Cannabinoids
Number of 
seizures
5F-MDMB-PICA 2 710
5F-MDMB-PINACA 864
4F-MDMB-BINACA 837
5F-Cumyl-PeGaClone 666
Cumyl-CH-MeGaClone 356
(b) Cannabinoids
Powder 
(grams)
4F-MDMB-BINACA 38 052.5
5F-MDMB-PICA 24 435.4
AM-2201 7 051.8
5F-MDMB-PINACA 5 320.6
Cumyl-CH-MeGaClone 3 101.4
(c) Cannabinoids
Herbal material 
(grams)
AMB-CHMICA 24 703.7
5F-MDMB-PICA 23 158.7
MDMB-CHMICA 17 056.4
5F-MDMB-PINACA 12 508.5
5F-Cumyl-PeGaClone 10 253.7
TABLE 2
The most commonly seized synthetic cannabinoids reported to the EU Early Warning System, numbers of seizures (a) 
and quantities seized reported in mass (b, c), 2019
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Focus on 4F-MDMB-BICA
4F-MDMB-BICA has been available on the drug market in 
Europe since at least March 2020. The substance is sold 
as a ‘legal’ replacement for cannabis and other controlled 
synthetic cannabinoids. Limited information suggests that 
4F-MDMB-BICA is a potent CB
1
 receptor agonist and, as 
such, shares some pharmacological similarities with THC, 
which is responsible for the major psychoactive effects of 
cannabis and other synthetic cannabinoids, such as 
JWH-018, which are under international control.
The available information suggests that 4F-MDMB-BICA is 
manufactured by chemical companies based in China. It is 
imported into Europe as bulk powders and then sold and 
distributed in wholesale and retail amounts within Europe 
either as a powder for processing into products or as 
finished consumer products.
As at October 2020, 4F-MDMB-BICA had been identified 
in 10 Member States and 108 seizures had been reported, 
including seizures of 5.6 kg of powder and 0.6 kg of 
smoking mixtures.
A total of 21 deaths associated with confirmed exposure to 
4F-MDMB-BICA have been reported by Hungary. The deaths 
occurred over a relatively short period of time, between May 
and August 2020. Further information on the role of 
4F-MDMB-BICA in the deaths is currently unavailable.
In prisons, alongside the adverse health effects, the market 
in synthetic cannabinoids has been linked to an increase in 
aggression, violence, bullying and debt. In some cases, this 
has caused a serious threat to the overall safety and 
security of the prison environment. This is concerning 
given the reports of seizures of 4F-MDMB-BICA in prisons 
and other custodial settings in at least five Member States.
There is no information on whether or not criminal groups 
are involved in the manufacture, trafficking and distribution 
of 4F-MDMB-BICA within Europe. The effect of the ongoing 
COVID-19 pandemic on the manufacture, trafficking, 
distribution and use of 4F-MDMB- BICA is currently 
unknown. However, seizures of bulk powders by national 
European customs agencies during the pandemic suggest 
that 4F-MDMB-BICA continues to be imported into and 
distributed within Europe. It is possible that, in the case of 
a reduction in the availability of cannabis and other 
synthetic cannabinoids in Europe, criminal groups, as well 
as drug users, may use a range of replacement 
substances, including 4F-MDMB-BICA.
4F-MDMB-BICA is subject to restrictive measures in 12 
Member States, Norway and Turkey. It is unknown if 
4F-MDMB-BICA is controlled in China, from where at least 
some of the substance on the European market has been 
sourced. 4F-MDMB-BICA has not been subject to 
assessment nor is it currently under assessment by the 
United Nations system.
Based on the information reported to the EMCDDA, there 
are indications that 4F-MDMB-BICA has the potential to 
spread rapidly in Europe. Of note is that the appearance of 
4F-MDMB-BICA on the market appears to have coincided 
with the recent decision to internationally control two 
closely related synthetic cannabinoids commonly found on 
the drug market in Europe: 4F-MDMB-BINACA and 
5F-MDMB-PICA. Therefore, it is possible that 4F-MDMB- 
BICA will be a replacement for these substances.
 I Benzodiazepines
Benzodiazepines are one of the most important groups of 
medicines that are specifically produced for sedation and 
to aid sleep. They are the most widely prescribed group of 
medicines in the world and are used to treat anxiety, 
insomnia, epilepsy and alcohol withdrawal. Given the large 
demand from consumers, they are a target for criminal 
groups that divert legitimate products from the market, sell 
unlicensed products or make fake versions of legitimate 
medicines. In the case of fake versions of medicines, new 
benzodiazepines are increasingly being used, particularly 
to produce fake diazepam tablets (Valium) and fake 
alprazolam tablets (Xanax).
As at 31 October 2020, the EMCDDA was monitoring 30 
new benzodiazepines — 21 (70 %) of which have been 
identified in Europe since 2015 (Figure 13). Despite this 
relatively large number, the market in Europe is dominated 
by only a handful of substances (Table 3), currently most 
notably etizolam and flualprazolam, although this may 
change in the next few months, as both these substances 
are now under international control.
In 2019, 5 716 seizures of new benzodiazepines were 
reported to the EU Early Warning System (5 622 (98 %) of 
which were reported by the Member States), reflecting 
around 13 % of the total number of seizures of new 
psychoactive substances (19 % in the Member States). 
This amounted to approximately 6.1 kg of material and 
2.4 million tablets (Figure 14).
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Potential changes to the market in new 
benzodiazepines
In the past few years, etizolam and flualprazolam, in 
particular, have played an increasingly important role in the 
new benzodiazepine market in some parts of Europe, 
especially in making fake diazepam and alprazolam tablets 
(Moritz et al., 2018; Schier et al., 2009; US CDC, 2018; 
Vallersnes et al., 2009). In 2020, based on 
a recommendation from the World Health Organization, 
the United Nations Commission on Narcotic Drugs 
decided to control etizolam and flualprazolam owing to the 
harms that they pose (Klar et al., 2016; Pap, 2016). These 
control measures came into effect on 3 November 2020 
(Klar et al., 2016). As a result, it is possible that other 
benzodiazepines will replace etizolam and flualprazolam.
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FIGURE 13
Number of benzodiazepines formally notified to the EU 
Early Warning System for the first time, 2005-2020  
(EU and EU+2)
FIGURE 14
Seizures of benzodiazepines reported to the EU Early 
Warning System: trends in number of seizures of powders 
and tablets, 2005-19 (EU and EU+2)
(a) Benzodiazepines
Number of 
seizures
Etizolam 4 747
Flualprazolam 434
Clonazolam 201
Diclazepam 82
Fonazepam 20
(b) Benzodiazepines
Powder 
(grams)
Etizolam 2 821.6
Flualprazolam 95.8
Diclazepam 40.8
Fluclotizolam 11.1
Flunitrazolam 10.3
(c) Benzodiazepines Tablets (units)
Etizolam 2 285 568
Flualprazolam 33 112
Clonazolam 19 492
Diclazepam 19 373
Fonazepam 11 371
TABLE 3
The most commonly seized benzodiazepines reported to the EU Early Warning System, numbers of seizures (a) and 
quantities seized reported in mass (b) and units (c), 2019
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Note: No benzodiazepines were formally notified to the  
EU Early Warning System for the first time between January 
and 31 October 2020.
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One such possibility is the re-emergence of 
flubromazolam, which was first notified in Europe in 2014 
(Tomassoni et al., 2017). Data from the Welsh Emerging 
Drugs & Identification of Novel Substances Project 
(Wedinos), the drug testing service operated by Public 
Health Wales, United Kingdom, appear to suggest that 
flubromazolam has recently re-emerged on the drug 
market in the United Kingdom and is being used to make 
fake diazepam, fake alprazolam, fake temazepam and fake 
zopiclone (Sutter et al., 2017). In some cases, the fake 
tablets were packaged into blister packs resembling 
legitimate products, which makes it more difficult for 
consumers to spot the fakes (Figure 15). Recent 
poisonings in the United Kingdom have been linked to 
flubromazolam sold as fake benzodiazepine medicines 
(Horth et al., 2018). In the United States, there has also 
been a recent increase in detections of this substance in 
toxicology analyses (NPS Discovery, 2020). While the 
amount of flubromazolam in the tablets is unknown, the 
substance appears to be a highly potent hypnotic (Adams 
et al., 2016; Arens et al., 2016; Edison et al., 2017).
I  Global markets, glocal threats: the case for strengthened early warning, preparedness and response measures
Over the past decade, the globalisation of drug markets 
and new technologies such as the internet have led to an 
increase in the number and types of risks facing people 
who use both new psychoactive substances and 
controlled drugs. These factors also create a resilient and 
highly dynamic new psychoactive substances market, 
making it more difficult to disrupt. Adding to this, the 
COVID-19 pandemic and related response measures have 
brought into sharp focus the importance of understanding 
how our health is intricately linked to our environment and 
globalisation, and how this can shape drug use.
Although evidence is currently limited, based on previous 
experiences of disruptions to drug markets, the impact of the 
pandemic could lead to localised or broader changes in drug 
use and patterns of use, as well as an increased risk of 
substitution, misselling, adulteration, contamination and 
dilution with a range of potentially dangerous and sometimes 
highly toxic substances; in some cases, this could cause 
outbreaks of mass poisonings, which could overload 
healthcare systems already struggling with the pandemic.
Providing reliable information is critical for an effective public 
health response, including prevention, health protection, 
treatment, supply reduction, and policy development and 
implementation. The EU Early Warning System and national 
early warning systems play a central role by providing such 
information in a timely manner and in sufficient detail to the 
right people, in the right place, at the right time, to allow them 
to assess the information and, where necessary, respond 
through timely and effective actions to prevent or reduce the 
risk of harm (EMCDDA, 2020b).
Given the growing complexity of the new psychoactive 
substances market and its strong links with the broader illicit 
drug market, there is a need to ensure that Europe continues 
to strengthen its ability to detect, assess and respond to 
existing and new threats in a timely and effective way, to 
prevent or reduce the public health and social harms caused 
by new psychoactive substances, whether this be by 
detecting and responding to a specific, immediate threat or 
through longer-term input into drug policy.
FIGURE 15
Fake tablets packaged in blister packs resembling 
legitimate products
Note: Sample of tablet purchased as ‘Diazepam Activis’ but found 
to contain flubromazolam and diazepam on analysis by Wedinos 
in May 2020. 
Photo © Wedinos, 2020.
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I Annex 1  Notifications of new psychoactive substances under the terms of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) — 2019
1.  APP-BINACA (N-(1-amino-1-oxo-3-phenylpropan-2-yl)-
1-butyl-1H-indazole-3-carboxamide), United Kingdom,
9 January 2019
2. 2F-QMPSB (quinolin-8-yl 3-((4,4-difluoropiperidin-1-yl)
sulfonyl)-4-methylbenzoate), Italy, 10 January 2019
3. Baclofen (4-amino-3-(4-chlorophenyl)butanoic acid),
Germany, 15 January 2019
4. EPT (N-(2-(1H-indol-3-yl)ethyl)-N-ethylpropan-1-
amine), Slovenia, 21 January 2019
5. Piperidylthiambutene (1-(4,4-di(thiophen-2-yl)
but-3-en-2-yl)piperidine), Slovenia, 22 January 2019
6. N-Ethylheptedrone (2-(ethylamino)-1-phenylheptan-
1-one), Hungary, 5 February 2019
7. Amantadine (adamantan-1-amine), Finland,
15 February 2019
8. Cyproheptadine (4-(5H-dibenzo[a,d][7]annulen-5-
ylidene)-1-methylpiperidine), Finland, 18 February
2019
9. Promethazine (N,N-dimethyl-1-(10H-phenothiazin-
10-yl)propan-2-amine), Finland, 25 February 2019
10. 1B-LSD (4-butyryl-N,N-diethyl-7-methyl-4,6,6a,7,8,9-
hexahydroindolo[4,3-fg]quinoline-9-carboxamide),
Austria, 7 March 2019
11. 4’-Ethyl-α-PVP (1-(4-ethylphenyl)-2-(pyrrolidin-1-yl)
pentan-1-one), Hungary, 7 March 2019
12. 5F-A-P7AICA (N-(adamantan-1-yl)-1-(5-fluoropentyl)-
1H-pyrrolo[2,3-b]pyridine-3-carboxamide), Germany,
2 April 2019
13. 2-Methyl-AP-237 (1-[2-methyl-4-(3-phenylprop-2-
en-1-yl)piperazin-1-yl]butan-1-one), Sweden, 3 April
2019
14. Bentazepam (5-phenyl-1,3,6,7,8,9-hexahydro-2H-[1]
benzothieno[2,3-e][1,4]diazepin-2-one), Sweden,
4 April 2019
15. 4F-furanylfentanyl (N-(4-fluorophenyl)-N-(1-
phenethylpiperidin-4-yl)furan-2-carboxamide), Italy,
15 April 2019
16. Isohexedrone (4-methyl-2-(methylamino)-1-
phenylpentan-1-one), Sweden, 29 April 2019
17. AP-237 (1-[4-(3-phenylprop-2-en-1-yl)piperazin-1-yl]
butan-1-one), Germany, 3 May 2019
18. Cinazepam (4-[[7-bromo-5-(2-chlorophenyl)-2-oxo-
1,3-dihydro-1,4-benzodiazepin-3-yl]
oxy]-4-oxo-butanoic acid), Sweden, 7 May 2019
19. 5F-JWH-398 (1-(5-fluoropentyl)-3-(4-chloro-1-
naphthoyl)indole), Germany, 7 May 2019
20. Hexylone (1-(1,3-benzodioxol-5-yl)-2-(methylamino)
hexan-1-one), Germany, 7 May 2019
21. Pagoclone (2-(7-chloro-1,8-naphthyridin-2-yl)-2,3-
dihydro-3-(5-methyl-2-oxohexyl)-1H-isoindol-1-one),
Sweden, 29 May 2019
22. Furanyl UF-17 (N-[2-(dimethylamino)cyclohexyl]-N-
phenyl-furan-2-carboxamide), United Kingdom, 5 June
2019
23. Isohexylone (1-(1,3-benzodioxol-5-yl)-4-methyl-2-
(methylamino)pentan-1-one), United Kingdom, 6 June
2019
24. 2C-B aminorex (5-(4-bromo-2,5-dimethoxy-phenyl)-
4,5-dihydrooxazol-2-amine), Sweden, 7 June 2019
25. 4-AcO-MPT (3-(2-[methyl(propyl)amino]ethyl)-1H-
indol-4-yl acetate), Sweden, 11 June 2019
26. BOD (2-(2,5-dimethoxy-4-methylphenyl)-2-
methoxyethan-1-amine), Slovenia, 17 June 2019
27. 6-BR-DMPEA (2-bromo-4,5-
dimethoxyphenethylamine), Denmark, 21 June 2019
28. 4-PrO-DMT (3-[2-(dimethylamino)ethyl]-1H-indol-4-yl
propanoate), Sweden, 2 July 2019
29. Pregabalin methyl ester (methyl 3-(aminomethyl)-5-
methylhexanoate), Sweden, 2 July 2019
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30. 2F-viminol (2-[di(butan-2-yl)amino]-1-[1-(2-
fluorobenzyl)-1H-pyrrol-2-yl]ethan-1-ol), Sweden,
4 July 2019
31. 4-Fluorophenibut (4-amino-3-(4-fluorophenyl)
butanoic acid), Sweden, 4 July 2019
32. 4-AcO-MALT ([3-[2-[allyl(methyl)amino]ethyl]-1H-
indol-4-yl] acetate), Netherlands, 5 July 2019
33. 3,4-CFP (1-(3-chloro-4-fluorophenyl)piperazine),
Poland, 10 July 2019
34. pBPP (1-(4-bromophenyl)piperazine), Poland, 11 July
2019
35. 4C-D (1-(2,5-dimethoxy-4-methylphenyl)butan-2-
amine), Netherlands, 12 July 2019
36. MDMB-CHMINACA (methyl 2-[1-(cyclohexylmethyl)-
1H-indazole-3-carboxamido]-3,3-dimethylbutanoate,
Poland, 12 July 2019
37. 4’-Methylhexedrone (2-(methylamino)-1-(4-
methylphenyl)-1-hexanone), Poland, 13 August 2019
38. N-ethylhexylone (1-(1,3-benzodioxol-5-yl)-2-
(ethylamino)hexan-1-one), Poland, 14 August 2019
39. Isotonitazene (N,N-diethyl-2-[[4-(1-methylethoxy)
phenyl]methyl]-5-nitro-1H-benzimidazole-1-
ethanamine, Belgium, 26 August 2019
40. 3F-α-PHiP (1-(3-fluorophenyl)-4-methyl-2-
(pyrrolidin-1-yl)pentan-1-one), Sweden, 27 August
2019
41. MDPEP (1-(1,3-benzodioxol-5-yl)-2-(pyrrolidin-1-yl)
heptan-1-one), Sweden, 6 September 2019
42. ADB-BUTINACA (N-(1-amino-3,3-dimethyl-1-
oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide),
Sweden, 23 September 2019
43. SL-164 (5-chloro-3-(4-chloro-2-methylphenyl)-2-
methyl-4(3H)-quinazolinone), Sweden, 24 September
2019
44. Crotonylfentanyl (N-phenyl-N-[1-(2-phenylethyl)-4-
piperidinyl]-2-butenamide), the Netherlands,
15 October 2019
45. N-ethylheptylone (1-(1,3-benzodioxol-5-yl)-2-
(ethylamino)heptan-1-one), Sweden, 18 October 2019
46. 1-Cp-LSD (4-(cyclopropanecarbonyl)-N,N-diethyl-7-
methyl-4,6,6a,7,8,9-hexahydroindolo[4,3-fg]
quinoline-9-carboxamide), Sweden, 21 October 2019
47. 4-MeO-MiPT (N-[2-(4-methoxy-1H-indol-3-yl)ethyl]-N-
methylpropan-2-amine), Sweden, 21 November 2019
48. Methyl 2-phenyl-2-(pyrrolidin-1-yl)acetate, Sweden,
22 November 2019
49. CUMYL-CBMICA (1-(cyclobutylmethyl)-N-(2-
phenylpropan-2-yl)-1H-indol-3-carboxamide),
Germany, 29 November 2019
50. Nitromethaqualone (3-(2-methoxy-4-nitrophenyl)-2-
methylquinazolin-4-one), Germany, 3 December 2019
51. 1-(4-Bromo-2,5-dimethoxyphenyl)ethanamine,
Germany, 6 December 2019
52. Xylazine (N-(2,6-dimethylphenyl)-5,6-dihydro-4H-1,3-
thiazin-2-amine), France, 13 December 2019
53. UR-144 degradant (3,3,4-trimethyl-1-(1-pentyl-1H-
indol-3-yl)pent-4-en-1-one), France, 18 December
2019
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I Annex 2  Notifications of new psychoactive substances under the terms of Regulation (EC) No 1920/2006 (as amended) and Council Framework Decision 2004/757/JHA (as amended) — 2020
1. α-Pyrrolidinocyclohexylphenone/α-PCYP
(2-cyclohexyl-1-phenyl-2-(pyrrolidin-1-yl)ethan-1-one),
Sweden, 9 January 2020
2. Methoxpropamine (2-(3-methoxyphenyl)-2-
(propylamino)cyclohexan-1-one), Denmark,
24 January 2020
3. 3F-α-PHP (1-(3-fluorophenyl)-2-(pyrrolidin-1-yl)
hexan-1-one), Sweden, 28 January 2020
4. BOH-PHP (1-phenyl-2-(pyrrolidin-1-yl)hexan-1-ol),
Slovenia, 2 March 2020
5. BENZYL-4CN-BINACA (N-benzyl-1-(4-cyanobutyl)-1H-
indazole-3-carboxamide), Sweden, 3 March 2020
6. Nefiracetam (N-(2,6-dimethylphenyl)-2-(2-
oxopyrrolidin-1-yl)acetamide), Sweden, 26 March
2020
7. N-Methyltryptamine (2-(1H-indol-3-yl)-N-methyl-
ethanamine), the Netherlands, 31 March 2020
8. Clozapine (3-chloro-6-(4-methylpiperazin-1-yl)-11H-
benzo[b][1,4]benzodiazepine), the United Kingdom,
15 April 2020
9. Citicoline (5-(4-amino-2-oxopyrimidin-1-yl)-3,4-
dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]
2-(trimethylammonium)ethyl phosphate), Germany,
22 April 2020
10. 4F-3-methyl-α-PVP (1-(4-fluoro-3-methylphenyl)-2-
(pyrrolidin-1-yl)pentan-1-one), Sweden, 30 April 2020
11. CUMYL-CBMINACA (1-(cyclobutylmethyl)-N-(2-
phenylpropan-2-yl)-1H-indazole-3-carboxamide),
Germany, 6 May 2020
12. Etazene (2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-1H-
benzimidazole-1-ethanamine), Poland, 1 June 2020
13. Brorphine (1-[1-[1-(4-bromophenyl)ethyl]-4-
piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one),
Sweden, 4 June 2020
14. BOH-2C-B (2-amino-1-(4-bromo-2,5-
dimethoxyphenyl)ethanol), Sweden, 9 June 2020
15. 5-MeO-AI (5-methoxy-2,3-dihydro-1H-inden-2-amine),
Poland, 18 June 2020
16. PTI-3 (N-({2-[1-(5-fluoropentyl)-1H-indol-3-yl]-1,3-
thiazol-4-yl}methyl)-2-methoxy-N-methylethanamine),
Hungary, 22 June 2020
17. Metodesnitazene (N,N-diethyl-2-[2-[(4-
methoxyphenyl)methyl]benzimidazol-1-yl]
ethanamine), Belgium, 26 June 2020
18. Cumyl-CB-MeGaClone (5-(cyclobutylmethyl)-2-(1-
methyl-1-phenyl-ethyl)pyrido[4,3-b]indol-1-one),
Hungary, 30 June 2020
19. 4F-MDMB-BICA (methyl 2-({[1-(4-fluorobutyl)-1H-
indol-3-yl]carbonyl}amino)-3,3-dimethylbutanoate),
Belgium, 2 July 2020
20. 5F-EMB-PICA (ethyl 2-[[1-(5-fluoropentyl)indole-3-
carbonyl]amino]-3-methyl-butanoate), Belgium, 3 July
2020
21. N,N-Diethylpentylone (1-(1,3-benzodioxol-5-yl)-2-
(diethylamino)pentan-1-one), Spain, 13 July 2020
22. 5-Br-DMT (2-(5-Bromo-1H-indol-3-yl)-N,N-
dimethylethan-1-amine), Slovenia, 17 July 2020
23. 5-Cl-DMT (2-(5-Chloro-1H-indol-3-yl)-N,N-
dimethylethan-1-amine), Slovenia, 17 July 2020
24. Isobutyrfentanyl (2-Methyl-N-phenyl-N-[1-(2-
phenylethyl)piperidin-4-yl]propanamide), Italy, 24 July
2020
25. 4,4-Dimethyl-1-phenyl-1-pyrrolidin-1-yl-pentan-3-one,
the United Kingdom, 24 July 2020
26. Nortilidine (ethyl 2-methylamino-1-phenylcyclohex-3-
ene-1-carboxylate), Poland, 30 July 2020
27. Mephedrene (N-methyl-1-(5-methyl-2-thienyl)
propan-2-amine), Germany, 31 July 2020
28. MDPHiP (1-(1,3-benzodioxol-5-yl)-4-methyl-2-
pyrrolidin-1-yl-pentan-1-one), Sweden, 19 August
2020
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29. 5F-EDMB-PICA (ethyl 2-(1-(5-fluoropentyl)-1H-indole-
3-carboxamido)-3,3-dimethylbutanoate), Hungary,
8 September 2020
30. Metonitazene (N,N-diethyl-2-[2-[(4-methoxyphenyl)
methyl]-5-nitro-benzimidazol-1-yl]ethanamine),
Germany, 14 September 2020
31. 3-Methoxyphenmetrazine (2-(3-methoxyphenyl)-3-
methylmorpholine), Finland, 16 September 2020
32. 5-MeO-DBT (N-butyl-N-[2-(5-methoxy-1H-indol-3-yl)
ethyl]butan-1-amine), Finland, 18 September 2020
33. Cumyl-BC-HpMeGaClone-221 ((5-(bicyclo[2.2.1]
hept-2-yl)methyl)-2-(2-phenylpropan-2-yl)-2,5-dihydro-
1H-pyrido[4,3-b]indol-1-one), Germany, 30 September
2020
34. 4F-ABINACA (N-(adamantan-1-yl)-1-(4-fluorobutyl)-
1H-indazole-3-carboxamide), Sweden, 9 October
2020
35. Carbonyl-bromadol ((4-bromophenyl)-(1-
(dimethylamino)-4-hydroxy-4-phenethylcyclohexyl)
methanone), Germany, 15 October 2020
36. 3F-N-ethylhexedrone (2-(ethylamino)-1-(3-
fluorophenyl)hexan-1-one), Sweden, 20 October 2020
37. AP-238 (1-[2,6-dimethyl-4-(3-phenylprop-2-enyl)
piperazin-1-yl]propan-1-one), Germany, 22 October
2020
38. O-AMKD (3-(4-acetyl-1-methylpiperidin-4-yl)phenyl
acetate), Germany, 27 October 2020
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GETTING IN TOUCH WITH THE EU
In person
All over the European Union there are hundreds of Europe Direct 
information centres. You can find the address of the centre nearest 
you at: https://europa.eu/european-union/contact_en
On the phone or by email
Europe Direct is a service that answers your questions about the 
European Union. You can contact this service:
•  by freephone: 00 800 6 7 8 9 10 11  
(certain operators may charge for these calls),
• at the following standard number: +32 22999696, or
• by email via: https://europa.eu/european-union/contact
FINDING INFORMATION ABOUT THE EU
Online 
Information about the European Union in all the official languages of 
the EU is available on the Europa website at: https://europa.eu
EU publications
You can download or order free and priced EU publications from:  
https://publications.europa.eu/en/publications.  
Multiple copies of free publications may be obtained by contacting 
Europe Direct or your local information centre (see  
https://europa.eu/european-union/contact).
About this report
In this update from the EU Early Warning System, the 
EMCDDA aims to provide insights into what is 
happening with new psychoactive substances in 
Europe, based on data from the agency’s early warning 
and risk-assessment activities. This report covers the 
period until October 2020.
About the EMCDDA
The European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) is the central source and 
confirmed authority on drug-related issues in Europe. 
For 25 years, it has been collecting, analysing and 
disseminating scientifically sound information on drugs 
and drug addiction and their consequences, providing 
its audiences with an evidence-based picture of the 
drug phenomenon at European level.
The EMCDDA’s publications are a prime source of 
information for a wide range of audiences including: 
policymakers and their advisors; professionals and 
researchers working in the drugs field; and, more 
broadly, the media and general public. Based in Lisbon, 
the EMCDDA is one of the decentralised agencies of 
the European Union.
